Logs: Bang Zheng
The following is a list of all job requests run via OpenSAFELY by Bang Zheng.
| Status | Organisation | Project | Workspace | Request ID | Backend | Jobs | Started | View request |
|---|---|---|---|---|---|---|---|---|
| Succeeded | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16272 | TPP | 2/2 | 2 years, 11 months ago 13 March 2023 18:49:54 UTC | View, Job request 16272 |
| Failed | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16270 | TPP | 0/1 | 2 years, 11 months ago 13 March 2023 18:25:23 UTC | View, Job request 16270 |
| Succeeded | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16268 | TPP | 2/2 | 2 years, 11 months ago 13 March 2023 17:11:17 UTC | View, Job request 16268 |
| Succeeded | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16266 | TPP | 1/1 | 2 years, 11 months ago 13 March 2023 16:30:49 UTC | View, Job request 16266 |
| Succeeded | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16264 | TPP | 2/2 | 2 years, 11 months ago 13 March 2023 16:00:59 UTC | View, Job request 16264 |
| Succeeded | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16254 | TPP | 1/1 | 2 years, 11 months ago 13 March 2023 14:16:32 UTC | View, Job request 16254 |
| Failed | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16250 | TPP | 0/1 | 2 years, 11 months ago 13 March 2023 13:43:10 UTC | View, Job request 16250 |
| Failed | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16241 | TPP | 1/2 | 2 years, 11 months ago 13 March 2023 10:53:39 UTC | View, Job request 16241 |
| Succeeded | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16225 | TPP | 1/1 | 3 years ago 10 March 2023 12:30:19 UTC | View, Job request 16225 |
| Succeeded | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16223 | TPP | 2/2 | 3 years ago 10 March 2023 11:54:12 UTC | View, Job request 16223 |
| Failed | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16220 | TPP | 1/2 | 3 years ago 10 March 2023 10:39:16 UTC | View, Job request 16220 |
| Succeeded | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16218 | TPP | 2/2 | 3 years ago 10 March 2023 10:20:13 UTC | View, Job request 16218 |
| Failed | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16217 | TPP | 0/2 | 3 years ago 10 March 2023 10:17:35 UTC | View, Job request 16217 |
| Failed | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16216 | TPP | 0/1 | 3 years ago 10 March 2023 09:19:31 UTC | View, Job request 16216 |
| Succeeded | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16215 | TPP | 2/2 | 3 years ago 10 March 2023 09:18:25 UTC | View, Job request 16215 |
| Succeeded | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16214 | TPP | 1/1 | 3 years ago 10 March 2023 09:11:05 UTC | View, Job request 16214 |
| Failed | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16213 | TPP | 0/2 | 3 years ago 10 March 2023 09:07:12 UTC | View, Job request 16213 |
| Failed | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16212 | TPP | 1/2 | 3 years ago 10 March 2023 08:37:52 UTC | View, Job request 16212 |
| Succeeded | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16211 | TPP | 2/2 | 3 years ago 10 March 2023 08:23:07 UTC | View, Job request 16211 |
| Failed | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16210 | TPP | 1/2 | 3 years ago 10 March 2023 07:52:11 UTC | View, Job request 16210 |
| Succeeded | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16209 | TPP | 2/2 | 3 years ago 10 March 2023 07:27:18 UTC | View, Job request 16209 |
| Succeeded | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 15981 | TPP | 1/1 | 3 years ago 03 March 2023 08:56:24 UTC | View, Job request 15981 |
| Succeeded | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 15980 | TPP | 1/1 | 3 years ago 03 March 2023 08:50:28 UTC | View, Job request 15980 |
| Succeeded | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 15979 | TPP | 1/1 | 3 years ago 03 March 2023 08:32:22 UTC | View, Job request 15979 |
| Failed | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 15977 | TPP | 1/2 | 3 years ago 03 March 2023 00:21:22 UTC | View, Job request 15977 |